Daily News Podcast

New cell-free DNA assays hold promise for lung cancer screening


 

A set of blood-based assays that search for abnormalities in cell-free DNA show moderately good sensitivity for detecting early-stage lung cancer. Also today, the FDA approves rituximab for the treatment of pemphigus vulgaris (prescribing information), obstructive sleep apnea with worsening hypoxemia raises metabolic syndrome risk, and the Department of Justice won’t defend the Affordable Care Act from a lawsuit. Listen to the MDedge Daily News podcast for all the details on today’s top news.

Recommended Reading

What is causing my patients’ macrocytosis?
MDedge Internal Medicine
Hip pain predicts arthritis mortality beyond comorbidities
MDedge Internal Medicine
Prostate cancer risk before age 55 higher for black men
MDedge Internal Medicine
Statin effect in prostate cancer may be caused by reduced inflammation
MDedge Internal Medicine
Raised LDL cholesterol, hsCRP tied to polymyalgia rheumatica, GCA
MDedge Internal Medicine
Smoking tied to localized prostate cancer recurrence, metastasis, death
MDedge Internal Medicine
FDA approves rituximab for treating pemphigus vulgaris
MDedge Internal Medicine
Aclidinium bromide for COPD: No impact on MACE
MDedge Internal Medicine
Malnourished U.S. inpatients often go untreated
MDedge Internal Medicine
Suicide rate jumps 30%
MDedge Internal Medicine